Affiliation:
1. Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
2. Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA
Abstract
Human studies, in combination with animal and cellular models, support glial cells as both major contributors to neurodegenerative diseases and promising therapeutic targets. Among glial cells, oligodendrocytes and Schwann cells are the myelinating glial cells of the central and peripheral nervous system, respectively. In this review, we discuss the contributions of these central and peripheral myelinating glia to the pathomechanisms of polyglutamine (polyQ) spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17. First, we highlight the function of oligodendrocytes in healthy conditions and how they are disrupted in polyQ SCA patients and diseased model systems. We then cover the role of Schwann cells in peripheral nerve function and repair as well as their possible role in peripheral neuropathy in polyQ SCAs. Finally, we discuss potential polyQ SCA therapeutic interventions in myelinating glial.
Reference121 articles.
1. Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view;Coarelli;F1000Res,2018
2. The spinocerebellar ataxias;Paulson;J. Neuroophthalmol.,2009
3. Spinocerebellar ataxia;Klockgether;Nat. Rev. Dis. Prim.,2019
4. Spinocerebellar ataxia 3 and Machado-Joseph disease: Clinical, molecular, and neuropathological features;Durr;Ann. Neurol.,1996
5. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7;Schoels;Prog. Neurobiol.,2013